Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00564889 · OUTCOME

Progression Free Survival (PFS)

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis · Source last updated 2013-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Duration of study (up to 3 years)

What was measured

Progression free survival (PFS) was defined as the time from registration to hematologic progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.

Groups in this outcome

Len/Cyc/Dex

Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Len/Cyc/Dex35

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Len/Cyc/Dex28.3Not reported12.1NAThe upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment
        group Id
        OG000
        lower Limit
        12.1
        upper Limit
        NA
        value
        28.3
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
description
Progression free survival (PFS) was defined as the time from registration to hematologic progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly
    id
    OG000
    title
    Len/Cyc/Dex
param Type
MEDIAN
reporting Status
POSTED
time Frame
Duration of study (up to 3 years)
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice